Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Evgeny Klyuchnikov; U Bacher; K Woo Ahn; J Carreras; Nicolaus-Martin Kröger; P N Hari; G H Ku; E Ayala; A I Chen; Y-B Chen; J B Cohen; C O Freytes; R P Gale; R T Kamble; M A Kharfan-Dabaja; H M Lazarus; R Martino; A Mussetti; B N Savani; H C Schouten; S Z Usmani; P H Wiernik; B Wirk; S M Smith; A Sureda; M Hamadani

doi:10.1038/bmt.2015.223

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Standard

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. / Klyuchnikov, Evgeny; Bacher, U; Woo Ahn, K; Carreras, J; Kröger, Nicolaus-Martin; Hari, P N; Ku, G H; Ayala, E; Chen, A I; Chen, Y-B; Cohen, J B; Freytes, C O; Gale, R P; Kamble, R T; Kharfan-Dabaja, M A; Lazarus, H M; Martino, R; Mussetti, A; Savani, B N; Schouten, H C; Usmani, S Z; Wiernik, P H; Wirk, B; Smith, S M; Sureda, A; Hamadani, M.

in: BONE MARROW TRANSPL, Jahrgang 51, Nr. 1, 05.10.2015, S. 58-66.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Klyuchnikov, E, Bacher, U, Woo Ahn, K, Carreras, J, Kröger, N-M, Hari, PN, Ku, GH, Ayala, E, Chen, AI, Chen, Y-B, Cohen, JB, Freytes, CO, Gale, RP, Kamble, RT, Kharfan-Dabaja, MA, Lazarus, HM, Martino, R, Mussetti, A, Savani, BN, Schouten, HC, Usmani, SZ, Wiernik, PH, Wirk, B, Smith, SM, Sureda, A & Hamadani, M 2015, 'Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma', BONE MARROW TRANSPL, Jg. 51, Nr. 1, S. 58-66. https://doi.org/10.1038/bmt.2015.223

APA

Klyuchnikov, E., Bacher, U., Woo Ahn, K., Carreras, J., Kröger, N-M., Hari, P. N., Ku, G. H., Ayala, E., Chen, A. I., Chen, Y-B., Cohen, J. B., Freytes, C. O., Gale, R. P., Kamble, R. T., Kharfan-Dabaja, M. A., Lazarus, H. M., Martino, R., Mussetti, A., Savani, B. N., ... Hamadani, M. (2015). Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. BONE MARROW TRANSPL, 51(1), 58-66. https://doi.org/10.1038/bmt.2015.223

Vancouver

Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger N-M, Hari PN et al. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. BONE MARROW TRANSPL. 2015 Okt 5;51(1):58-66. https://doi.org/10.1038/bmt.2015.223

Bibtex

@article{4f09c607b85543bda4c47e232bf43bee,

title = "Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma",

abstract = "Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning (RIC) allo-HCT or first auto-HCT during 2000-2012 were included. Rituximab-naive patients were excluded. Allo-HCT recipients were younger, more heavily pretreated and had a longer interval between diagnosis and HCT. The 5-year probabilities of non-relapse mortality (NRM), relapse/progression, PFS and overall survival (OS) for auto-HCT vs allo-HCT groups were 4% vs 27% (P<0.001), 61% vs 20% (P<0.001), 36% vs 51% (P=0.07) and 59% vs 54% (P=0.7), respectively. On multivariate analysis, auto-HCT was associated with reduced risk of NRM (relative risk (RR)=0.20; P=0.001). Within the first 11 months post HCT, auto- and allo-HCT had similar risks of relapse/progression and PFS. Beyond 11 months, auto-HCT was associated with higher risk of relapse/progression (RR=21.3; P=0.003) and inferior PFS (RR=3.2; P=0.005). In the first 24 months post HCT, auto-HCT was associated with improved OS (RR=0.42; P=0.005), but in long-time survivors (beyond 24 months) it was associated with inferior OS (RR=3.6; P=0.04). RIC allo-HCT as the first transplant approach can provide improved PFS and OS, in long-term survivors.Bone Marrow Transplantation advance online publication, 5 October 2015; doi:10.1038/bmt.2015.223.",

author = "Evgeny Klyuchnikov and U Bacher and {Woo Ahn}, K and J Carreras and Nicolaus-Martin Kr{\"o}ger and Hari, {P N} and Ku, {G H} and E Ayala and Chen, {A I} and Y-B Chen and Cohen, {J B} and Freytes, {C O} and Gale, {R P} and Kamble, {R T} and Kharfan-Dabaja, {M A} and Lazarus, {H M} and R Martino and A Mussetti and Savani, {B N} and Schouten, {H C} and Usmani, {S Z} and Wiernik, {P H} and B Wirk and Smith, {S M} and A Sureda and M Hamadani",

year = "2015",

month = oct,

day = "5",

doi = "10.1038/bmt.2015.223",

language = "English",

volume = "51",

pages = "58--66",

journal = "BONE MARROW TRANSPL",

issn = "0268-3369",

publisher = "NATURE PUBLISHING GROUP",

number = "1",

}

RIS

TY - JOUR

T1 - Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

AU - Klyuchnikov, Evgeny

AU - Bacher, U

AU - Woo Ahn, K

AU - Carreras, J

AU - Kröger, Nicolaus-Martin

AU - Hari, P N

AU - Ku, G H

AU - Ayala, E

AU - Chen, A I

AU - Chen, Y-B

AU - Cohen, J B

AU - Freytes, C O

AU - Gale, R P

AU - Kamble, R T

AU - Kharfan-Dabaja, M A

AU - Lazarus, H M

AU - Martino, R

AU - Mussetti, A

AU - Savani, B N

AU - Schouten, H C

AU - Usmani, S Z

AU - Wiernik, P H

AU - Wirk, B

AU - Smith, S M

AU - Sureda, A

AU - Hamadani, M

PY - 2015/10/5

Y1 - 2015/10/5

N2 - Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning (RIC) allo-HCT or first auto-HCT during 2000-2012 were included. Rituximab-naive patients were excluded. Allo-HCT recipients were younger, more heavily pretreated and had a longer interval between diagnosis and HCT. The 5-year probabilities of non-relapse mortality (NRM), relapse/progression, PFS and overall survival (OS) for auto-HCT vs allo-HCT groups were 4% vs 27% (P<0.001), 61% vs 20% (P<0.001), 36% vs 51% (P=0.07) and 59% vs 54% (P=0.7), respectively. On multivariate analysis, auto-HCT was associated with reduced risk of NRM (relative risk (RR)=0.20; P=0.001). Within the first 11 months post HCT, auto- and allo-HCT had similar risks of relapse/progression and PFS. Beyond 11 months, auto-HCT was associated with higher risk of relapse/progression (RR=21.3; P=0.003) and inferior PFS (RR=3.2; P=0.005). In the first 24 months post HCT, auto-HCT was associated with improved OS (RR=0.42; P=0.005), but in long-time survivors (beyond 24 months) it was associated with inferior OS (RR=3.6; P=0.04). RIC allo-HCT as the first transplant approach can provide improved PFS and OS, in long-term survivors.Bone Marrow Transplantation advance online publication, 5 October 2015; doi:10.1038/bmt.2015.223.

AB - Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning (RIC) allo-HCT or first auto-HCT during 2000-2012 were included. Rituximab-naive patients were excluded. Allo-HCT recipients were younger, more heavily pretreated and had a longer interval between diagnosis and HCT. The 5-year probabilities of non-relapse mortality (NRM), relapse/progression, PFS and overall survival (OS) for auto-HCT vs allo-HCT groups were 4% vs 27% (P<0.001), 61% vs 20% (P<0.001), 36% vs 51% (P=0.07) and 59% vs 54% (P=0.7), respectively. On multivariate analysis, auto-HCT was associated with reduced risk of NRM (relative risk (RR)=0.20; P=0.001). Within the first 11 months post HCT, auto- and allo-HCT had similar risks of relapse/progression and PFS. Beyond 11 months, auto-HCT was associated with higher risk of relapse/progression (RR=21.3; P=0.003) and inferior PFS (RR=3.2; P=0.005). In the first 24 months post HCT, auto-HCT was associated with improved OS (RR=0.42; P=0.005), but in long-time survivors (beyond 24 months) it was associated with inferior OS (RR=3.6; P=0.04). RIC allo-HCT as the first transplant approach can provide improved PFS and OS, in long-term survivors.Bone Marrow Transplantation advance online publication, 5 October 2015; doi:10.1038/bmt.2015.223.

U2 - 10.1038/bmt.2015.223

DO - 10.1038/bmt.2015.223

M3 - SCORING: Journal article

C2 - 26437062

VL - 51

SP - 58

EP - 66

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 1

ER -